Current perspectives on recurrent pituitary adenoma: The role and timing of surgery vs adjuvant treatment.
Caroline HayhurstPeter N TaylorAndrew J LansdownNachi PalaniappanDafydd Aled ReesJohn Stephen DaviesPublished in: Clinical endocrinology (2019)
The clinical course of pituitary adenoma can be highly variable. Aggressive pituitary tumours may require multimodal therapy with multiple operations. Even standard pituitary adenomas exhibit relatively high long-term recurrence rates and delayed intervention is often required. The indications for revision surgery in the endoscopic era are expanding for both functioning and nonfunctioning tumours, including access to the cavernous sinus and intracranial compartments. Although revision surgery can be challenging, it has been demonstrated to be both safe and effective. The question of the use of early radiotherapy in pituitary adenoma remains controversial. Our increasing understanding of pituitary tumour biology facilitates individualized treatment and surveillance protocols, with early intervention in high-risk adenoma subtypes. In this review, we discuss the treatment options for recurring pituitary tumours and focus on the role of revision surgery.
Keyphrases
- minimally invasive
- growth hormone
- coronary artery bypass
- total knee arthroplasty
- randomized controlled trial
- early stage
- surgical site infection
- total hip arthroplasty
- public health
- squamous cell carcinoma
- percutaneous coronary intervention
- combination therapy
- chronic pain
- pain management
- atrial fibrillation
- smoking cessation